Anti-tumor Activity of FCE 23762, a New Doxorubicin Derivative
Author Information
Author(s): M. Ripamonti, G. Pezzoni, E. Pesentil, A. Pastoril, M. Faraol, A. Bargiotti, A. Suarato, F. Spreaficol, M. Grandil
Primary Institution: Farmitalia C. Erba, Research Center, Oncology Dept.
Hypothesis
FCE 23762 is more effective than doxorubicin against multidrug-resistant tumors.
Conclusion
FCE 23762 shows significant anti-tumor activity against various cancer models, including those resistant to doxorubicin.
Supporting Evidence
- FCE 23762 is over 80 times more potent than doxorubicin.
- It maintains anti-tumor activity against doxorubicin-resistant cell lines.
- Most treated mice with MX-1 human mammary carcinoma were cured.
- FCE 23762 was effective against multiple types of cancer, including murine and human tumors.
- The compound is lipophilic, allowing for effective oral administration.
- FCE 23762 does not cross the blood-brain barrier.
- Significant efficacy was observed in models resistant to L-PAM and cDDP.
Takeaway
FCE 23762 is a new drug that works better than an old one called doxorubicin, especially on tough cancer cells that usually don't respond to treatment.
Methodology
The study involved synthesizing FCE 23762 and testing its anti-tumor activity in various murine and human cancer models through different administration routes.
Limitations
The study does not address the long-term effects of FCE 23762 or its potential toxicity in humans.
Participant Demographics
Adult mice of various strains were used for testing.
Want to read the original?
Access the complete publication on the publisher's website